Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

INSERMU379/ORS-PACA, Marseilles, France.
Antiviral therapy (Impact Factor: 3.14). 02/2005; 10(1):53-61.
Source: PubMed

ABSTRACT To disentangle the impact of adherence from that of injecting drug status and depressive syndrome on HIV clinical progression in a cohort of highly active antiretroviral therapy (HAART)-treated HIV patients infected through drug use.
MANIF 2000 is a French cohort of HIV-infected drug users with scheduled medical visits every 6 months. Only patients enrolled in the MANIF 2000 cohort who had a CD4 cell count >200 cells/microl at HAART initiation were selected. The follow-up period included all post-HAART initiation visits.
HIV clinical progression was defined as either AIDS-related death or reaching a CD4 level <200 cells/microl. Adherence was assessed using a self-administered questionnaire and a structured face-to-face interview. Depressive symptoms were evaluated by a Center for Epidemiologic Studies Depression Scale (CES-D) score at each visit. Cox proportional hazards model was used to calculate crude and adjusted relative hazards and 95% confidence intervals and thus identify independent predictors of clinical progression.
Of the 305 HAART-treated patients in the cohort, 243 had CD4 cell count >200 cells/microl at HAART initiation. At the first visit after HAART initiation, median CD4 cell count was 466 cells/microl and 45% had undetectable viral load. Injecting drug users accounted for 17% of the study group. Over the follow-up period, 32 patients experienced HIV clinical progression. Probable depression was encountered in 46% of patients and non-adherence in 31% of the sample. After adjustment on baseline CD4 cell count, predictors of clinical progression were: having a higher level of cumulative non-adherence over the follow-up period [HR (95% CI)=1.2 (1.1-1.3) per 10% increase] and having a high score of depressive symptoms following HAART initiation [HR (95% CI)=5.3 (2.21-3.0)].
Although depressive syndrome is known to influence non-adherence behaviours that are amongst the major reasons for clinical progression, it is also a predictor of clinical progression in HIV-infected intravenous drug users on HAART, independently of non-adherence behaviours. HIV care providers should be more sensitive to depressive symptoms in order to detect them early and supply HIV patients with specific care. Further research is needed to determine whether treating depressive symptoms may improve adherence and thus delay disease progression and mortality.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Depression is the most common neuropsychiatric complication in HIV-infected patients and may occur in all phases of the infection. Accurately, diagnosing major depressive disorder in the context of HIV is an ongoing challenge to clinicians and researchers, being complicated by the complex biological, psychological, and social factors associated with the HIV illness. Evidences exist to support the importance of improving the identification of depressive symptoms and their adequate treatment. Depression has long been recognized as a predictor of negative clinical outcomes in HIV-infected patients, such as reducing medication adherence, quality of life, and treatment outcome, and possibly worsening the progression of the illness and increasing mortality. By analyzing the most relevant studies (MEDLINE, EMBASE, PsycLit, Cochrane Library), the review discusses the epidemiology and the main clinical features of depression in HIV-infected patients, the causal pathways linking depression and HIV infection, the validity of screening tools, and the efficacy of different treatment approaches, including psychosocial interventions, psychopharmacology as well as HIV-specific health psychology health service models.
    Current Psychiatry Reports 01/2015; 17(1):530. DOI:10.1007/s11920-014-0530-4 · 3.05 Impact Factor
  • Source
    Open Journal of Medical Psychology 01/2014; 3(01):60-69. DOI:10.4236/ojmp.2014.31008
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumo Objetivo: Mensurar a prevalência de sintomas depressivos de acordo com Inventário de Depressão de Beck em pacientes portadores do HIV/Aids em um hospital de referência na cidade de Florianópolis – SC. Método: Foi realizado um estudo transversal que avaliou 27 portadores do HIV/Aids atendidos em enfermaria médica, ambulatório e Hospital Dia do Hospital Nereu Ramos (HNR) -Florianópolis – SC. Foram avaliadas variáveis sociodemográficas e relacionadas aos transtornos depressivos. Foi utilizado o Inventário de Depressão de Beck, e como ponto de corte o seguinte índice: <18 normal, e maior ou igual à 18 possível depressão. Resultados: O ponto de corte considerado como sugestivo para depressão foi atingido por 11(40,7%) dos participantes. Não houve diferença estatisticamente significativa quando avaliada a presença de sintomas depressivos de acordo com o tipo de atendimento que o paciente estava recebendo (p 0,143), e de acordo com o gênero (p 0,102). Abstract Objective: To estimate the prevalence of depression based on Beck Depression Inventory in patients with HIV/ Aids in a referential hospital located in Florianópolis-SC. Methods: It was made a transversal study witch evaluated 27 patients with HIV/Aids treated in Nereu Ramos Hospital, in Florianópolis-SC. It was evaluated social demographic data and also data related with depression disorders. It was used the Beck Depression Inventory and the levels used were: <18 normal and e" 18 possible depression. Results: The cut-off score considered as depression diagnose was reached by 11 (40,7%) patients. There were no statistical significance when it was evaluated the occurrence of depression in association with kind of attainment that this patients were receiving (p 0,102). There was, also, no statistical difference according to gender. Conclusions: The prevalence of depression according to Beck Depression Inventory in HIV/Aids patients was 40,7%.

Full-text (2 Sources)

Available from
May 29, 2014